UK Shuffle Will Undermine Stem Cell Progress
This article was originally published in SRA
Executive Summary
At first glance the new UK coalition government's plans to cut bureaucracy in the healthcare sector, including streamlining the functions of certain regulatory bodies, sound like an answer to the prayers of the regulated industry and patients alike. But they should tread with caution: this may merely be a post-election quick fix that could lead to a setback in critical areas such as global stem cell research.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: